| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon and other elements have been incorporated into drug molecules, primarily as quantitative tracers during drug development. Deuteration is of concern because of its possible impact on the pharmacokinetics and metabolic characteristics of drugs [1].
|
|---|---|
| References | |
| Additional Infomation |
Triamcinolone acetonide esters. It is an anti-inflammatory glucocorticoid used topically to treat various skin conditions. In some cases, it can also be administered via intralesional, intramuscular, or intra-articular injection.
|
| Molecular Formula |
C24H31FO6
|
|---|---|
| Molecular Weight |
440.53472161293
|
| Exact Mass |
440.248
|
| CAS # |
352431-33-5
|
| Related CAS # |
Triamcinolone acetonide;76-25-5
|
| PubChem CID |
633097
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
576.9±50.0 °C at 760 mmHg
|
| Flash Point |
302.7±30.1 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.589
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
31
|
| Complexity |
925
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
F[C@@]12[C@]3(C=CC(C=C3CCC1C1C[C@@H]3[C@](C(CO)=O)([C@@]1(C)C[C@@H]2O)OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])O3)=O)C
|
| InChi Key |
YNDXUCZADRHECN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3
|
| Chemical Name |
12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2700 mL | 11.3500 mL | 22.6999 mL | |
| 5 mM | 0.4540 mL | 2.2700 mL | 4.5400 mL | |
| 10 mM | 0.2270 mL | 1.1350 mL | 2.2700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07010744
Conditions:DyspepsiaLink: https://clinicaltrials.gov/ct2/show/NCT07312721
Conditions:Helicobacter Pylori Infection|Chronic Gastritis|Peptic Ulcer DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04895280
Conditions:Full-thickness Rotator Cuff Tear|Rotator Cuff Tendinitis
Title:Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers
Status:Not yet recruiting
updateDate:2024-05-20
Ctid:NCT06421038
Link: https://clinicaltrials.gov/ct2/show/NCT06421038
Conditions:Aphthous Stomatitis (Major) (Minor)|Treatment ComplianceLink: https://clinicaltrials.gov/ct2/show/NCT04115644
Conditions:Full Thickness Rotator Cuff Tear|Rotator Cuff TendinitisLink: https://clinicaltrials.gov/ct2/show/NCT04216017
Conditions:Humeral FracturesLink: https://clinicaltrials.gov/ct2/show/NCT05635942
Conditions:Helicobacter PyloriLink: https://clinicaltrials.gov/ct2/show/NCT02519738
Conditions:Other Abnormal Granulation Tissue NosLink: https://clinicaltrials.gov/ct2/show/NCT02767492
Conditions:Knee OsteoarthritisLink: https://clinicaltrials.gov/ct2/show/NCT02126878
Conditions:BursitisLink: https://clinicaltrials.gov/ct2/show/NCT01967329
Conditions:Helicobacter Pylori InfectionLink: https://clinicaltrials.gov/ct2/show/NCT02369068
Conditions:Pelvic PainLink: https://clinicaltrials.gov/ct2/show/NCT04006340
Conditions:Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation|Helicobacter Pylori InfectionLink: https://clinicaltrials.gov/ct2/show/NCT01692756
Conditions:Anterior Cruciate Ligament (ACL) TearsLink: https://clinicaltrials.gov/ct2/show/NCT02592629
Conditions:Shoulder PainLink: https://clinicaltrials.gov/ct2/show/NCT03491995
Conditions:Helicobacter InfectionsLink: https://clinicaltrials.gov/ct2/show/NCT01769365
Conditions:Helicobacter Pylori InfectionLink: https://clinicaltrials.gov/ct2/show/NCT00398866
Conditions:OsteoarthritisLink: https://clinicaltrials.gov/ct2/show/NCT02613455
Conditions:Lateral Epicondylitis|Tennis ElbowLink: https://clinicaltrials.gov/ct2/show/NCT01306786
Conditions:Helicobacter Pylori InfectionLink: https://clinicaltrials.gov/ct2/show/NCT00742846
Conditions:Adhesive CapsulitisLink: https://clinicaltrials.gov/ct2/show/NCT01760824
Conditions:Helicobacter Pylori InfectionLink: https://clinicaltrials.gov/ct2/show/NCT00140803
Conditions:Age-Related Macular DegenerationLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022010-32
Condition:Castration Resistent Prostate cancerLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012442-23
Condition:Osteoarthritis of hip jointLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004666-61
Condition:Acute gout (patients who are refractory or contraindicated to NSAIDs and/or colchicine)Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004226-16
Condition:Subjects with chronic rhinosinusitis without nasal polyps, who have not had previous sinus surgery might be eligible for participation in this trial.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001678-34
Condition:Irritative contact dermatitis.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005400-14
Condition:Diabetic Maculopathy: Clinically significant macular oedemaTo understand the effects of intravitreal triamcinolone (IVTA) in the treatment of clinically significant macular edema (CSME) in diabetics who have concurrent cataract which requires intervention.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005138-35
Condition:Proliferative vitreoretinopathy following open globe trauma.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006729-28
Condition:The objective of this study is to compare the efficacy of equivalent doses of IM triamcinolone acetonide and oral prednisolone in controlling a symptomatic flare in patients with established RA.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002466-11
Condition:Classic or predominantly classic age related macular degenerationLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005043-97
Condition:Macular oedema affects 29% of diabetic patients and is the main cause of visual impairment. Previous studies show that diffuse macular oedema carries a particularly poor prognosis despite laser photocoagulation.Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000397-45
Condition:Diabetic macular oedema affecting vision and refractory to laser treatmentLink: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001991-37
Condition:Proliferative VitreoretinopathyThis is a scarring process that occurs in patients who have developed a retinal detachment. It is the primary cause of failure in retinal detachment surgery and occurs in 5-10% cases.Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
